MX9705572A - Complejos estables para el suministro de farmacos que contienen lipidos y metodos para su produccion. - Google Patents

Complejos estables para el suministro de farmacos que contienen lipidos y metodos para su produccion.

Info

Publication number
MX9705572A
MX9705572A MX9705572A MX9705572A MX9705572A MX 9705572 A MX9705572 A MX 9705572A MX 9705572 A MX9705572 A MX 9705572A MX 9705572 A MX9705572 A MX 9705572A MX 9705572 A MX9705572 A MX 9705572A
Authority
MX
Mexico
Prior art keywords
drug delivery
production
complexes
methods
lipid
Prior art date
Application number
MX9705572A
Other languages
English (en)
Other versions
MXPA97005572A (es
Inventor
Xiang Gao
Leaf Huang
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Publication of MX9705572A publication Critical patent/MX9705572A/es
Publication of MXPA97005572A publication Critical patent/MXPA97005572A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Abstract

Se describen novedosos complejos estables para la entrega de drogas, concentrados, biologicamente activos, listos para ser utilizados y que contienen lípidos, métodos para su utilizacion. La actividad biologica de los complejos producidos, es comparable a la de las formulaciones preparadas de acuerdo con el método del arte anterior basado en el mezclado conjunto; y, al ser purificados, los complejos producidos mediante el método de la presente invencion, tienen una concentracion de 50 a 500 veces la de los componentes de los complejos formados mediante el mezclado conjunto. El método descrito en la presente, permite la produccion en gran escala de sistemas entregadores de drogas y que contienen lípidos, utiles para la terapia basada en los genes, y para otras aplicaciones.
MXPA/A/1997/005572A 1995-01-23 1997-07-23 Complejos estables para el suministro de farmacosque contienen lipidos y metodos para su produccion MXPA97005572A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08376701 1995-01-23
US08/376,701 US5795587A (en) 1995-01-23 1995-01-23 Stable lipid-comprising drug delivery complexes and methods for their production

Publications (2)

Publication Number Publication Date
MX9705572A true MX9705572A (es) 1998-06-28
MXPA97005572A MXPA97005572A (es) 1998-10-30

Family

ID=

Also Published As

Publication number Publication date
AU4703796A (en) 1996-08-14
DK0814777T3 (da) 2003-03-03
DE69624801D1 (de) 2002-12-19
US20100184953A1 (en) 2010-07-22
IL116856A0 (en) 1996-07-23
AU709773B2 (en) 1999-09-09
ATE227563T1 (de) 2002-11-15
ZA96503B (en) 1996-08-07
PT814777E (pt) 2003-03-31
JP4074338B2 (ja) 2008-04-09
CA2211118A1 (en) 1996-08-01
US20130281382A1 (en) 2013-10-24
US8771728B2 (en) 2014-07-08
US20080153166A1 (en) 2008-06-26
WO1996022765A1 (en) 1996-08-01
EP0814777B1 (en) 2002-11-13
CA2211118C (en) 2009-06-30
US20120178702A1 (en) 2012-07-12
DE69624801T2 (de) 2003-04-10
US5795587A (en) 1998-08-18
EP0814777A1 (en) 1998-01-07
US7655468B2 (en) 2010-02-02
ES2186769T3 (es) 2003-05-16
JPH10512882A (ja) 1998-12-08
US7993672B2 (en) 2011-08-09
CN1177291A (zh) 1998-03-25

Similar Documents

Publication Publication Date Title
IL116856A0 (en) Stable-lipid- comprising drug delivery complexes and methods for their production
HU9200823D0 (en) Process for the production of cyclical carbamide derivatives and medical preparations containing them as active agents
AU7576896A (en) Lipopolyamines as transfection agents and their pharmaceutical applications
ES2058411T3 (es) Sustancia fr 901228 y su preparacion.
AU6701890A (en) Process for the production of biologically active protein
UA43348C2 (uk) Водна фармацевтична композиція, що включає фактор росту нерва (варіанти) та ліофілізований фармацевтичний склад
HUT76511A (en) Benzoyl derivatives, preparation and use thereot
TW225532B (es)
EG18334A (en) Pyrozoline compounds and their use as pesticides
EP0657534A4 (en) ANTIALLERGIC AGENT.
MY102918A (en) Purified antineoplaston fractions and methods of treating neoplastic disease.
MY115211A (en) Novel amino acid derivatives, their preparation and use
ES2002053A6 (es) Procedimiento para la obtencion de peptidos inihiobidores de renina que contienen grupos hidroxi.
ES8403157A1 (es) Un metodo de preparar sustancias biologicamente activas que tienen actividad anti-tumoral.
DK0952853T3 (da) Konjugat omfattende et aktivt middel, et polypeptid og en polyether
AR002272A1 (es) Uso de amidas de fenilciclohexilcarboxilicos
DK347788A (da) Teicoplaninlignende forbindelser, fremgangsmaade og mikroorganisme til fremstilling deraf og farmaceutisk praeparat indeholdende saadanne forbindelser
ATE25708T1 (de) Biologisch aktive konjugate, ihre herstellung und ihre anwendung.
CA2072797A1 (en) Use of tri (n-butyl) phosphate at low ph in solutions of biologically active proteins for enhanced virucidal activity
IL125474A0 (en) Solid instant-release forms of administration and process for producing the same
MD970230A (en) Diamine ether diclavulanate and process for preparation thereof
AU625831B2 (en) Solubilization of t-pa
AU578125B2 (en) Pyrazine diazohydroxide compounds
EP0332999A3 (en) Peptides with inhibitory activity of enzymatic systems, process for their preparation and pharmaceutical compositions containing them
UA5743C2 (uk) Препарат тканинних біологічно активних речовин, який має регенаторну дію, та спосіб його одержання